Skip to Main Content

Advertisement

Skip Nav Destination

Evaluating New Myeloma Agent Combinations in Lenalidomide-Refractory Patients

December 30, 2021

Dr. Chari reports results from a trial of daratumumab plus carfilzomib-dexamethasone in patients with lenalidomide-refractory disease.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X